Online citations, reference lists, and bibliographies.
← Back to Search

Standard Chemotherapy Options And Clinical Trials Of Novel Agents For Mesothelioma

M. Zauderer
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Despite recent dramatic advances in many solid tumors, malignant mesothelioma remains challenging to treat. Historically, because of the modest number of cases globally and the substantial geographic distribution of patients, large randomized clinical trials were difficult and lengthy to complete, and thus, interest from pharmaceutical companies was limited. Additionally, financial support from various funding agencies is limited for this orphan disease. Consequently, most studies of systemic therapy for mesothelioma were small phase II trials. Despite these limitations, several standards of care were established. This chapter reviews standard cytotoxic chemotherapy treatment for malignant mesothelioma and discusses many novel agents recently and currently under investigation in clinical trials. The roles of surgery, radiation treatment, and combined modality therapy are covered in accompanying chapters. Furthermore, the ongoing development of immunotherapeutic agents is discussed in an accompanying chapter by Hassan and colleagues.
This paper references
10.1007/BF00944192
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma
G. Falkson (2004)
10.18632/oncotarget.9515
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230
C. Blackwell (2016)
10.1016/J.BBRC.2003.12.074
Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
J. Neuzil (2004)
10.1038/nchembio.1084
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
S. Knutson (2012)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1016/S0140-6736(15)01311-2
A new standard for malignant pleural mesothelioma
M. Zauderer (2016)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1016/j.celrep.2016.06.097
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1
Matthew Locke (2016)
10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z
WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS
S. Kumar-Singh (1997)
10.1016/S0140-6736(12)61767-X
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
J. Bissler (2013)
Phase II trial of vindesine in malignant pleural mesothelioma.
C. Boutin (1987)
10.1038/ncomms10292
BAP1/ASXL1 recruitment and activation for H2A deubiquitination
Danny D. Sahtoe (2016)
Efficiency of recombinant human TNF in human cancer therapy.
F. Lejeune (2006)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience
H. Lerner (1983)
10.1038/modpathol.2013.58
Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck
F. Göke (2013)
10.1002/cncr.23371
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions
A. Dar (2008)
10.1158/1078-0432.CCR-11-2375
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
M. Ladanyi (2012)
10.1182/blood-2009-12-259523
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Güllü T Görgün (2010)
10.1016/j.ab.2008.01.018
Arginine and glycine stimulate creatine synthesis in creatine transporter 1-deficient lymphoblasts.
V. Leuzzi (2008)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
10.1016/j.jtcvs.2009.06.027
Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Mor-Li Hartman (2010)
10.1200/JCO.2012.48.4626
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
P. Sonneveld (2013)
10.1158/1078-0432.CCR-10-2345
Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
G. Shapiro (2011)
10.1056/NEJM197111182852108
Tumor angiogenesis: therapeutic implications.
J. Folkman (1971)
10.1023/A:1006421706540
Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma
Y. Oh (2004)
10.1200/JCO.2000.18.4.708
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.
H. Fine (2000)
Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast.
A. Hoque (2003)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1038/onc.2009.280
Mutant Fibroblast Growth Factor Receptor 3 Induces Intracellular Signaling and Cellular Transformation in a Cell Type- and Mutation-Specific Manner
E. di Martino (2009)
10.1016/J.JNUTBIO.2005.12.001
Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates.
W. Jobgen (2006)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1016/j.cllc.2013.12.008
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
A. Tsao (2014)
10.1126/science.1221711
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
A. Dey (2012)
10.1093/JNCI/80.9.698-A
Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
A. Alberts (1988)
10.1016/j.lungcan.2008.08.014
Functional inactivation of NF2/merlin in human mesothelioma.
Claudio Thurneysen (2009)
10.1023/A:1011139918558
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
J. Steele (2001)
10.1007/s10637-012-9876-9
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors
M. Gordon (2012)
10.1200/JCO.2009.27.3649
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
V. Gregorc (2010)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1038/bjc.2014.220
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou (2014)
10.1084/jem.20131141
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
O. Abdelwahab (2013)
10.1158/1535-7163.MCT-11-0184
An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
K. Hook (2012)
10.3816/CLC.2010.n.005
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1007/BF00570490
Phase I study of recombinant human tumor necrosis factor
K. Kimura (2004)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
10.3892/or.2013.2948
Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Makio Moriya (2014)
10.1242/jcs.013136
Aurora-A: the maker and breaker of spindle poles
A. Barr (2007)
10.1016/J.LUNGCAN.2007.09.018
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
H. Avet‐Loiseau (1998)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1097/JTO.0b013e31817c73ec
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
G2 checkpoint abrogators as anticancer drugs.
T. Kawabe (2004)
10.1016/j.jtho.2016.08.075
P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.
G. Scagliotti (2016)
10.1007/BF02170889
A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy
J. Schwartz (1989)
10.1200/JCO.2004.11.120
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
F. Izzo (2004)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1007/BF00273404
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma
E. Mbidde (2004)
Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway.
L. Liu (2004)
10.1002/cncr.30026
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
R. Orlowski (2016)
10.1038/cddis.2011.135
Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair
A. Bulgar (2012)
10.1200/JCO.2005.14.167
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
W. Kelly (2005)
10.1097/00000421-199812000-00017
Phase II trial of topotecan for the treatment of mesothelioma.
A. Maksymiuk (1998)
10.1073/pnas.0611653104
Impaired angiogenesis in aminopeptidase N-null mice
R. Rangel (2007)
10.1038/nature09784
The Polycomb complex PRC2 and its mark in life
R. Margueron (2011)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
10.1517/13543784.16.7.1111
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
M. Duvic (2007)
10.1007/s00280-007-0500-1
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
G. Gordon (2007)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1128/MCB.01578-08
Loss of the Tumor Suppressor Gene NF2, Encoding Merlin, Constitutively Activates Integrin-Dependent mTORC1 Signaling
M. López-Lago (2009)
10.1016/j.lungcan.2012.02.022
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).
S. Cedrés (2012)
10.1586/14737140.2015.1069186
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer
J. Syrios (2015)
10.1038/nrc1779
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S. Minucci (2006)
10.1073/pnas.1303800110
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
S. Knutson (2013)
10.1038/nature11606
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
M. T. McCabe (2012)
10.1081/CNV-120003538
Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Mesothelioma
K. Skubitz (2002)
10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
10.1021/acsmedchemlett.5b00037
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
J. E. Campbell (2015)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1158/0008-5472.CAN-13-1702
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
M. Allen (2014)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1038/nrd4204
PI3K and cancer: lessons, challenges and opportunities
D. Fruman (2014)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.1038/sj.bjc.6605856
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
T-S Yang (2010)
10.1002/1097-0142(19921115)70:10<2547::AID-CNCR2820701025>3.0.CO;2-F
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A southwest oncology group study
B. Zidar (1992)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1074/jbc.M306275200
Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells*
T. Marumoto (2003)
10.1016/S0140-6736(11)61742-X
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
M. Pavel (2011)
10.1158/1541-7786.MCR-14-0038
Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
L. Marek (2014)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.ccr.2012.06.032
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
O. Abdelwahab (2012)
10.1046/j.1365-2184.2003.00266.x
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
K. Vermeulen (2003)
10.1111/j.1349-7006.2011.01958.x
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker
Masashi Takawa (2011)
10.1097/JTO.0b013e31828c2b26
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
10.1007/s00280-011-1618-8
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
H. Carol (2011)
10.1083/jcb.200503165
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane
T. Okada (2005)
10.1038/nrclinonc.2010.21
mTOR signaling and drug development in cancer
J. Dancey (2010)
Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
F. Curnis (2002)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.3.CO;2-J
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck (1999)
10.1016/J.CYTOGFR.2005.01.003
Fibroblast growth factor signaling in tumorigenesis.
R. Grose (2005)
10.1182/blood-2011-11-395749
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
S. Kumar (2012)
10.1097/JTO.0b013e31820e1a25
Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy
M. A. Hoda (2011)
10.4103/1477-3163.77274
Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism
S. Loganathan (2011)
10.1186/1756-0500-5-482
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
A. Bearz (2011)
10.1158/1535-7163.MCT-08-0860
Epigenetics in cancer: Targeting chromatin modifications
Leigh Ellis (2009)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1016/S0959-8049(01)00428-2
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
J. Van Meerbeeck (2002)
10.1021/BI00386A011
Selective inhibition by methoxyamine of the apurinic/apyrimidinic endonuclease activity associated with pyrimidine dimer-DNA glycosylases from Micrococcus luteus and bacteriophage T4.
M. Liuzzi (1987)
10.1016/S0959-8049(02)00668-8
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
P. Baas (2003)
10.1016/J.LUNGCAN.2007.08.031
Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option.
A. Razak (2008)
10.1158/1078-0432.CCR-15-2225
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
S. Dolly (2016)
10.1126/SCIENCE.277.5331.1501
Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216.
C. Y. Peng (1997)
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
P. Sørensen (1985)
10.1200/JCO.2009.24.2669
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
J. Yao (2010)
10.1007/s10585-004-3150-2
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma
B. Davidson (2004)
10.1002/(SICI)1097-0142(19991115)86:10<1985::AID-CNCR15>3.0.CO;2-H
Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma
H. Kindler (1999)
10.1158/1078-0432.CCR-06-1405
Aurora Kinases: New Targets for Cancer Therapy
R. Carvajal (2006)
10.1158/2159-8290.CD-13-0050
Identification of targetable FGFR gene fusions in diverse cancers.
Y. Wu (2013)
10.1371/journal.pone.0020351
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
A. Dutt (2011)
10.1165/AJRCMB.25.5.4539
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
X. Cao (2001)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1021/jm2009327
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
D. Sutherlin (2011)
10.1038/nrc2780
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
10.1038/nrd1930
Epigenetic therapy of cancer: past, present and future
C. Yoo (2006)
10.1093/ANNONC/MDF046
Malignant pleural mesothelioma: a phase II trial with docetaxel.
D. Vorobiof (2002)
10.1126/SCIENCE.7997877
Cell cycle control and cancer.
L. Hartwell (1994)
10.1248/BPB.30.1819
The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease.
N. Itoh (2007)
10.1097/JTO.0b013e318194f991
A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL
J. Symanowski (2009)
10.1016/J.CTRV.2006.01.008
Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma.
C. Porta (2006)
10.1016/0277-5379(91)90134-Y
Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy
H. Gamm (1991)
10.1158/1078-0432.CCR-09-1621
Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
H. V. van Laarhoven (2010)
10.1586/14737140.8.2.293
Current concepts in malignant pleural mesothelioma
A. Kaufman (2008)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1002/pbc.22430
Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
J. Maris (2010)
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma.
C. Linder (1998)
10.1111/j.1440-1843.2012.02193.x
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model
Trung The Van (2012)
10.1002/GCC.2870090114
Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma
You Yong Lu (1994)
Phase II trial of mitomycin in malignant mesothelioma.
D. Bajorin (1987)
10.1038/bcj.2016.55
Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
S. Jacobus (2016)
10.1023/A:1008346925273
Caelyx in malignant mesothelioma: a phase II EORTC study.
P. Baas (2000)
10.1038/nrd2792
The FGF family: biology, pathophysiology and therapy
A. Beenken (2009)
10.1002/hed.21007
Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma
A. Mazumdar (2009)
10.1007/s10637-014-0121-6
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study
G. Falchook (2014)
10.1158/1078-0432.CCR-06-1101
In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion
P. Szlosarek (2006)
10.1038/nrd2133
Anticancer activities of histone deacetylase inhibitors
J. E. Bolden (2006)
10.3816/CLC.2004.N.020
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
10.1007/BF00267953
A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
P. Creaven (2004)
10.1097/JTO.0b013e3181c5e366
Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials
P. Paik (2010)
10.1038/35077213
Proliferation, cell cycle and apoptosis in cancer
G. Evan (2001)
10.1016/S0140-6736(08)61039-9
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
R. Motzer (2008)
10.1158/1078-0432.CCR-07-0536
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
A. Sartore-Bianchi (2007)
10.1093/annonc/mdv591
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.
A. Tolcher (2016)
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
10.1016/S0169-5002(00)00166-5
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
10.1200/JCO.1990.8.1.151
Phase II trial of carboplatin in the management of malignant mesothelioma.
D. Raghavan (1990)
10.1200/JCO.2010.29.8216
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
A. Palumbo (2010)
10.1371/journal.pone.0065489
BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
S. Busacca (2013)
10.1007/BF00263135
A phase II study of vincristine in malignant mesothelioma — a negative report
G. Mårtensson (2004)
10.1056/NEJM197108122850711
Transplacental carcinogenesis by stilbestrol.
J. Folkman (1971)
10.1016/j.lungcan.2016.03.013
Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
G. Epstein Shochet (2016)
10.1158/1078-0432.CCR-11-1536
Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
M. Manfredi (2011)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.1007/BF00397922
Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas
B. Wiedenmann (2004)
10.1002/path.3979
BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma
S. Busacca (2012)
10.1016/S0959-8049(97)00183-4
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
T. Sahmoud (1997)
10.1023/A:1026438215309
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
N. Vogelzang (1999)
10.1016/S0169-5002(01)00250-1
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
M. Kosty (2001)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1016/J.LUNGCAN.2004.10.005
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
10.1200/JCO.2012.42.1784
Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
P. Szlosarek (2013)
10.1016/j.lungcan.2010.03.005
Antiproliferative effect of Aurora kinase targeting in mesothelioma.
S. Crispi (2010)
10.1111/nyas.12122
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases
D. Lebwohl (2013)
10.1038/nrc1323
The evolution of thalidomide and its IMiD derivatives as anticancer agents
J. Bartlett (2004)
10.1097/JTO.0b013e318260dfb9
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
D. Fennell (2012)
10.1056/NEJMoa1009290
Everolimus for advanced pancreatic neuroendocrine tumors.
J. Yao (2011)
10.1182/BLOOD-2006-06-025999
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
M. Duvic (2007)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
10.1007/BF00175403
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
B. Zidar (2004)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
D. Mintzer (1985)
10.1158/1541-7786.MCR-09-0300
MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo
J. Huck (2010)
A new approach to the study of the base-excision repair pathway using methoxyamine.
M. Liuzzi (1985)
10.1200/JCO.2014.32.15_SUPPL.TPS8120
Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.
P. López (2014)
10.1016/j.ejca.2013.05.008
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
M. O'Brien (2013)
10.1038/81183
Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F. Curnis (2000)
10.1007/BF00685720
Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B
N. Vogelzang (2004)
10.1016/j.ejca.2009.10.005
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
V. Gregorc (2010)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1111/j.1349-7006.2010.01499.x
Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV‐1‐infected T‐cells in vitro
Mariko Tomita (2010)
10.1126/scitranslmed.3001451
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
J. Weiss (2010)
10.1097/JTO.0000000000000360
SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
S. Ou (2015)
10.1016/j.lungcan.2011.06.007
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.
S. Kao (2012)
10.2147/DDDT.S75221
Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells
F. Wang (2015)
10.1200/JCO.2011.37.4918
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia
L. Garderet (2012)
10.1002/ijc.25202
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
B. Delage (2010)
10.1200/JCO.2005.02.0933
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
P. Ascierto (2005)
10.1016/j.ajpath.2011.05.060
Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.
Q. Li (2011)
10.1038/bjc.1996.465
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck (1996)
10.1056/NEJMra1112635
Targeting epigenetic readers in cancer.
M. Dawson (2012)
10.1158/1078-0432.CCR-08-1579
Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma
F. Vandermeers (2009)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
10.1016/j.lungcan.2013.11.011
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
P. Zucali (2014)
10.1073/pnas.0803379105
Drug-sensitive FGFR2 mutations in endometrial carcinoma
A. Dutt (2008)
10.1182/BLOOD-2012-02-408922
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
L. Rosiñol (2012)
10.1200/JCO.2009.26.7765
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Evan S Glazer (2010)
10.4161/cbt.7.9.6415
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer
X. Zhang (2008)
10.1016/S1470-2045(13)70586-2
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
M. Reck (2014)
10.1158/0008-5472.CAN-12-3950
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
R. Liao (2013)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
10.1158/0008-5472.CAN-09-3746
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
N. Turner (2010)
10.2217/fon.14.290
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
S. Popat (2015)
10.1158/1078-0432.CCR-09-2755
Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo
K. Kudo (2010)
10.1111/J.1745-7270.2007.00363.X
Reversible histone acetylation involved in transcriptional regulation of WT1 gene.
Yangguang Shao (2007)
10.1196/annals.1322.011
Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic Drugs
A. Corti (2004)
10.1056/NEJMoa1109653
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
J. Baselga (2012)
10.1016/j.lungcan.2012.06.011
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
N. Campbell (2012)
10.1002/jcb.22316
Spreading of mesothelioma cells is rapamycin‐sensitive and requires continuing translation
E. Ranzato (2009)
10.1093/annonc/mdu348.25
1220TiPMULTI-ARM, NONRANDOMIZED, OPEN-LABEL PHASE IB STUDY TO EVALUATE FP1039/GSK3052230 WITH CHEMOTHERAPY IN NSCLC AND MPM WITH DEREGULATED FGF PATHWAY SIGNALING.
P. Garrido (2014)
10.1200/JCO.2011.39.6820
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
P. Sonneveld (2012)
10.1517/13543784.2014.934808
The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials
A. Synakiewicz (2014)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
S. Kumar-Singh (1997)
10.1074/JBC.M207500200
Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif*
G. Colombo (2002)
10.1021/ml500409n
MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
T. Sells (2015)
10.1200/JCO.2006.10.5460
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
R. Orlowski (2007)
10.1016/J.LUNGCAN.2004.12.002
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2005)
10.1007/BF00175408
Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study
J. D. Cowan (2004)
10.1038/nature03097
Cell-cycle checkpoints and cancer
M. Kastan (2004)
10.1158/0008-5472.CAN-07-6307
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
F. Hilberg (2008)
10.1016/j.jtho.2016.01.014
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
10.1021/jm900431g
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
G. Roth (2009)
10.1002/cncr.10923
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
P. Illei (2003)
10.1016/S0140-6736(12)61134-9
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
D. Franz (2013)
10.1016/j.lungcan.2010.12.004
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
10.1073/PNAS.72.9.3666
An endotoxin-induced serum factor that causes necrosis of tumors.
E. Carswell (1975)
10.1007/BF00877244
A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion
A. Mittelman (2004)
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar